On March 28, the FDA approved Imfinzi for use in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single-agent Imfinzi as adjuvant treatment after radical cystectomy, ...

Gilead's Trodelvy and Merck's Keytruda improved progression-free survival in PD-L1+ metastatic TNBC in a Phase 3 trial with ...

The study enrolled patients with a PD-L1 combined positive score (CPS) of 10 or more, matching Keytruda's label in first-line ...

Five-year data from the KEYNOTE-048 trial support the use of pembrolizumab and pembrolizumab-chemotherapy as standards of care, researchers wrote.

where tumours expressed PD-L1 (CPS ≥1). Patients who received the Keytruda and chemotherapy combination, with or without bevacizumab, enjoyed 19.8 months of overall survival compared to 16.3 ...

US biotech major Gilead Sciences (Nasdaq: GILD) today announced positive top-line results from the Phase III ...

In the subset of patients whose tumors expressed PD-L1 (combined positive score [CPS] ≥10), median progression-free survival (PFS) improved from 15.2 months with standard chemotherapy ...

The use of Trodelvy plus Keytruda in patients with previously untreated PD-L1+ metastatic TNBC is investigational, and the safety and efficacy of this use have not been established. The ...

Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 22C3 pharmDx (Code SK006) assay has received European IVDR ...